

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai HeartCare Medical Technology Corporation Limited

上海心璋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in relation to the proposed amendments to the Company’s articles of association (the “**Articles of Association**”).

The Listing Rules were amended by, among others, adopting a uniform set of 14 core standards for shareholder protections for issuers regardless of their place of incorporation as set out in Appendix 3 to the Listing Rules which became effective on January 1, 2022. The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes to make certain amendments to the Articles of Association to (i) conform to the said core standards for shareholder protections; and (ii) incorporate certain housekeeping changes (collectively, the “**Proposed Amendments**”). The Board proposes to make the Proposed Amendments by way of adoption of a new set of articles of association (the “**New Articles of Association**”) in substitution for, and to the exclusion of, the existing Articles of Association. Reference is also made to the Company’s announcement dated October 10, 2022, circular dated October 24, 2022 and the extraordinary general meeting held on November 9, 2022, pursuant to which the Company has proposed to revise its Articles of Association to prepare for the proposed issue of A shares, listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange and compliance with the relevant rules and requirements (the “**A Shares Listing Articles of Association**”). The shareholders of the Company (the “**Shareholders**”) approved of the A Shares Listing Articles of Association on November 9, 2022 and the amendments will take effect and be put into force after the listing of the Company’s A shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The Proposed Amendments (if adopted by the Shareholders) will therefore take effect prior to the A Shares Listing Articles of Association if it is adopted prior to the aforementioned listing, and the A Share Listing Articles of Association shall only take effect after listing of the Company’s A shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

The Proposed Amendments and the proposed adoption of the New Articles of Association are subject to the approval by the Shareholders by way of a special resolution at the forthcoming annual general meeting (the “AGM”) to be convened by the Company. A circular containing, among others, details of the Proposed Amendments brought about by the adoption of the New Articles of Association, together with a notice convening the AGM, will be despatched to the Shareholders in due course.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
Wang Guohui
Chairman of the Board

Shanghai, March 20, 2023

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui and Mr. Chen Shaoxiong; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.